Karen Katen named president of Pfizer Pharma worldwide
Effective April 1, Karen Katen will become president of the PfizerPharmaceuticals Group and executive vice president of Pfizer Inc. As president of PPG, Ms Katen will have responsibility for the company's worldwide pharmaceutical organization. Since 1995, she has served as president of the Pfizer US pharmaceutical organization, a position she will retain, and, in 1997, Ms Katen became executive vice president of PPG.
Commenting on Ms Katen's appointment, Pfizer chief executive Henry McKinnell said her "US organization built an outstanding sales force which, for the sixth straight year, has been acknowledged as the best in the USA. She now brings this record of accomplishment to our worldwide pharmaceutical operation."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze